spacer
home > ebr > autumn 2018 > determining peptides
PUBLICATIONS
European Biopharmaceutical Review

Determining Peptides

Therapeutic peptides are often applied via the following routes: intramuscular (IM), intraperitoneal (IP), intravenous (IV), or inhalative. Only a few peptides are stable in the stomach (acidic plus pepsin digestion) and the intestine (trypsin digestion) after oral application. Determination in plasma is very complex, as far as selectivity is concerned, because millions of endogenous peptides and proteins can be found in plasma.

Usually, the determination of a drug in plasma starts with some questions:

• How much of that drug is applied per kg body weight
• Which route of application is used (IM, IP, IV, oral, or inhalative)
• Is anything known about the first pass effect (leading to metabolites and, therefore, lowering the parent drug concentration)
• Does the molecule show a high volume of bodily distribution (which often means that the molecule shows very lipophilic characteristics or high tissue attraction and, therefore, a fast elimination half-life and low concentration levels in plasma

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Professor Hermann Mascher, bioanalytical consultant and founder of pharm-analyt Labor, has more than 100 publications in peer reviewed journals (with more than a 230 impact factor). Hermann is the inventor of three patents for biomarkers in the area of rare lysosomal storage diseases and has developed analytical methods for dozens of peptides.
spacer
Professor Hermann Mascher
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement